NCT06290466View on ClinicalTrials.gov

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

February 8, 2023

Study Completion Date

February 8, 2023

Conditions
Advanced Breast Cancer
Interventions
DRUG

Low dose group

300 mg,single dose.

DRUG

High dose group

400 mg, single dose.

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Ahon Pharmaceutical Co., Ltd.

OTHER

NCT06290466 - Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects | Biotech Hunter | Biotech Hunter